Thibaut Mazard

Learn More
INTRODUCTION KRAS and EGFR ectodomain-acquired mutations in patients with metastatic colorectal cancer (mCRC) have been correlated with acquired resistance to anti-EGFR monoclonal antibodies (mAbs). We investigated the frequency, co-occurrence, and distribution of acquired KRAS and EGFR mutations in patients with mCRC refractory to anti-EGFR mAbs using(More)
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Disclosure: The authors disclose no potential conflicts of interest. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Circulating tumor cells (CTCs) in blood are promising new biomarkers(More)
BACKGROUND Incorporation of multiple enrichment biomarkers into prospective clinical trials is an active area of investigation, but the factors that determine clinical trial enrollment following a molecular prescreening program have not been assessed. PATIENTS AND METHODS Patients with 5-fluorouracil-refractory metastatic colorectal cancer at the MD(More)
  • 1